Jorge Willian Leandro Nascimento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jorge Willian Leandro Nascimento has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Ademar Alves da Silva Filho
Departamento de Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal de Juiz de Fora, R. José Lourenço Kelmer s/n, Campus Universitário, Juiz de Fora 36036-900, MG, Brazil
4 shared publications - Aline Corrêa Ribeiro
Universidade Federal de Juiz de Fora
3 shared publications - Carlos Alberto Mourão Júnior
Universidade Federal de Juiz de Fora
2 shared publications - Ernane Cláudio Souza-Júnior
Doutor em Química de Produtos Medicinais e Naturais, University of Iowa, USA
2 shared publications - Flávia de Paula Gonçalves Guimarães
Universidade Federal de Juiz de Fora (UFJF)
2 shared publications - Priscila de Faria Pinto
Departamento de Bioquímica, Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil
2 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 82 (1) , 46
Effects of acute, subacute, and chronic exercise on plasma s-Klotho levels: a systematic review and meta-analysis
Exercise exerts beneficial effects on multiple physiological systems, influencing biomarkers associated with aging processes and chronic diseases. This systematic review and meta-analysis aimed to evaluate the acute, subacute, and chronic effects of exercise on s-Klotho levels in healthy individuals and patients with chronic diseases. A comprehensive search was conducted in electronic databases. Included studies were randomized and non-randomized studies assessing the effects of aerobic, resistance, or combined exercise on s-Klotho levels. Interventions were classified as acute (single session), subacute (< 12 weeks), or chronic (≥ 12 weeks). Risk of bias was assessed using RoB 2 and ROBINS-I tools, and quality of evidence was evaluated with the GRADE framework. Forty-one studies were included in the qualitative synthesis, and 30 in the meta-analysis, comprising 2,765 participants (18–85 years). Twenty-five involved healthy individuals, while 21 included patients with chronic diseases. Acute and subacute aerobic exercise increased s-Klotho levels in healthy individuals (SMD 0.69; 95%CI 0.41–0.97) and diseased populations (SMD 0.62; 95%CI 0.11–1.12). Chronic exercise (12–36 weeks) showed significant increases in healthy (SMD 0.57; 95%CI 0.33–0.82) and diseased populations (SMD 1.51; 95%CI 0.87–2.16). Resistance exercise thrice weekly demonstrated the highest effect (SMD 1.60; 95%CI 0.81–2.38). Most studies had high risk of bias, with quality of evidence ranging from very low to moderate. Exercise significantly increases s-Klotho levels, with acute and subacute aerobic sessions benefiting healthy and diseased populations, while chronic resistance exercise elicited greater responses in diseased populations. Despite promising findings, low methodological quality suggests cautious interpretation.
- 2 May 2026
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 82 (1) , 46
Open AccessEffects of acute, subacute, and chronic exercise on plasma s-Klotho levels: a systematic review and meta-analysis
Exercise exerts beneficial effects on multiple physiological systems, influencing biomarkers associated with aging processes and chronic diseases. This systematic review and meta-analysis aimed to evaluate the acute, subacute, and chronic effects of exercise on s-Klotho levels in healthy individuals and patients with chronic diseases. A comprehensive search was conducted in electronic databases. Included studies were randomized and non-randomized studies assessing the effects of aerobic, resistance, or combined exercise on s-Klotho levels. Interventions were classified as acute (single session), subacute (< 12 weeks), or chronic (≥ 12 weeks). Risk of bias was assessed using RoB 2 and ROBINS-I tools, and quality of evidence was evaluated with the GRADE framework. Forty-one studies were included in the qualitative synthesis, and 30 in the meta-analysis, comprising 2,765 participants (18–85 years). Twenty-five involved healthy individuals, while 21 included patients with chronic diseases. Acute and subacute aerobic exercise increased s-Klotho levels in healthy individuals (SMD 0.69; 95%CI 0.41–0.97) and diseased populations (SMD 0.62; 95%CI 0.11–1.12). Chronic exercise (12–36 weeks) showed significant increases in healthy (SMD 0.57; 95%CI 0.33–0.82) and diseased populations (SMD 1.51; 95%CI 0.87–2.16). Resistance exercise thrice weekly demonstrated the highest effect (SMD 1.60; 95%CI 0.81–2.38). Most studies had high risk of bias, with quality of evidence ranging from very low to moderate. Exercise significantly increases s-Klotho levels, with acute and subacute aerobic sessions benefiting healthy and diseased populations, while chronic resistance exercise elicited greater responses in diseased populations. Despite promising findings, low methodological quality suggests cautious interpretation.
- Open Access
- 28 August 2025
- Published by Scientific Electronic Archives in Scientific Electronic Archives
- Vol. 18 (5)
Attenuation of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice by Licochalcone A
Multiple sclerosis (MS) is an autoimmune inflammatory and demyelinating disease of the central nervous system (CNS) that affects more than 2.5 million people worldwide. The experimental autoimmune encephalomyelitis (EAE) is an appropriate and a well-establish model for studying the pathogenesis of MS. Licochalcone A (LicoA) is a chalcone obtained from the roots of Glycyrrhiza inflata (Fabaceae) that has in vitro immunomodulatory effects. EAE was induced in C57BL/6 mice with myelin oligodendrocyte glycoprotein and we have investigated the treatment of LicoA in this animal model. LicoA was isolated from G. inflata and was orally administered during the development of EAE. The capacity of absorption and distribution of LicoA, after gavage, to the brain was performed by HPLC. The clinical course and body weight were performed daily, cytokines (ELISA) and oxygen radicals production (NO and H2O2) were investigated. The CNS sections were stained by hematoxylin and eosin. After the treatment, by HPLC, at the first time, we analyzed the penetration between tissue/plasma, and our results showed that LicoA was present in serum and reached the mice brain with a good distribution. LicoA reduced clinical score and severity of EAE-mice, as well as inhibited H2O2, NO, TNF-α, IFN-γ and, mainly, IL-17 production. Histopathological analysis confirmed that LicoA treatment significantly reduced the numbers of inflammatory infiltrates and attenuates neurological damages in the CNS. These findings demonstrate that the oral treatment of LicoA significantly ameliorated the inflammatory signs associated with EAE, since it is effective at reducing both disease onset and severity.
- 28 August 2025
- Published by Scientific Electronic Archives in Scientific Electronic Archives
- Vol. 18 (5)
Open AccessAttenuation of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice by Licochalcone A
Multiple sclerosis (MS) is an autoimmune inflammatory and demyelinating disease of the central nervous system (CNS) that affects more than 2.5 million people worldwide. The experimental autoimmune encephalomyelitis (EAE) is an appropriate and a well-establish model for studying the pathogenesis of MS. Licochalcone A (LicoA) is a chalcone obtained from the roots of Glycyrrhiza inflata (Fabaceae) that has in vitro immunomodulatory effects. EAE was induced in C57BL/6 mice with myelin oligodendrocyte glycoprotein and we have investigated the treatment of LicoA in this animal model. LicoA was isolated from G. inflata and was orally administered during the development of EAE. The capacity of absorption and distribution of LicoA, after gavage, to the brain was performed by HPLC. The clinical course and body weight were performed daily, cytokines (ELISA) and oxygen radicals production (NO and H2O2) were investigated. The CNS sections were stained by hematoxylin and eosin. After the treatment, by HPLC, at the first time, we analyzed the penetration between tissue/plasma, and our results showed that LicoA was present in serum and reached the mice brain with a good distribution. LicoA reduced clinical score and severity of EAE-mice, as well as inhibited H2O2, NO, TNF-α, IFN-γ and, mainly, IL-17 production. Histopathological analysis confirmed that LicoA treatment significantly reduced the numbers of inflammatory infiltrates and attenuates neurological damages in the CNS. These findings demonstrate that the oral treatment of LicoA significantly ameliorated the inflammatory signs associated with EAE, since it is effective at reducing both disease onset and severity.
- Open Access
- 25 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6742
The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review
This study focuses on the use of thiopurines for treating inflammatory bowel diseases (IBD). These drugs undergo enzymatic changes within the body, resulting in active and inactive metabolites that influence their therapeutic effects. The research examines the role of genetic polymorphisms in the enzyme thiopurine S-methyltransferase (TPMT) in predicting the therapeutic response and adverse effects of thiopurine treatment. The TPMT genotype variations impact the individual responses to thiopurines. Patients with reduced TPMT activity are more susceptible to adverse reactions (AEs), such leukopenia, hepatotoxicity, pancreatitis, and nausea, which are common adverse effects of thiopurine therapy. The therapeutic monitoring of the metabolites 6-thioguanine nucleotides (6-TGN) and 6-methyl mercaptopurine (6-MMP) is proposed to optimize treatment and minimize AEs. Patients with higher 6-TGN levels tend to have better clinical responses, while elevated 6-MMP levels are linked to hepatotoxicity. Genotyping for TPMT before or during treatment initiation is suggested to tailor dosing strategies and enhance treatment efficacy while reducing the risk of myelosuppression. In conclusion, this study highlights the importance of considering genetic variations and metabolite levels in optimizing thiopurine therapy for IBD patients, focusing on balance therapeutic efficacy with the prevention of adverse effects and contributing to personalized treatment and better patient outcomes.
- 25 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6742
Open AccessThe Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review
This study focuses on the use of thiopurines for treating inflammatory bowel diseases (IBD). These drugs undergo enzymatic changes within the body, resulting in active and inactive metabolites that influence their therapeutic effects. The research examines the role of genetic polymorphisms in the enzyme thiopurine S-methyltransferase (TPMT) in predicting the therapeutic response and adverse effects of thiopurine treatment. The TPMT genotype variations impact the individual responses to thiopurines. Patients with reduced TPMT activity are more susceptible to adverse reactions (AEs), such leukopenia, hepatotoxicity, pancreatitis, and nausea, which are common adverse effects of thiopurine therapy. The therapeutic monitoring of the metabolites 6-thioguanine nucleotides (6-TGN) and 6-methyl mercaptopurine (6-MMP) is proposed to optimize treatment and minimize AEs. Patients with higher 6-TGN levels tend to have better clinical responses, while elevated 6-MMP levels are linked to hepatotoxicity. Genotyping for TPMT before or during treatment initiation is suggested to tailor dosing strategies and enhance treatment efficacy while reducing the risk of myelosuppression. In conclusion, this study highlights the importance of considering genetic variations and metabolite levels in optimizing thiopurine therapy for IBD patients, focusing on balance therapeutic efficacy with the prevention of adverse effects and contributing to personalized treatment and better patient outcomes.
- Open Access
- 17 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 1071
Identification of Asiaticoside from Centella erecta (Apiaceae) as Potential Apyrase Inhibitor by UF-UHPLC-MS and Its In Vivo Antischistosomal Activity
Schistosomiasis, caused by parasites of the genus Schistosoma, is a neglected disease with high global prevalence, affecting more than 240 million people in several countries. Praziquantel (PZQ) is the only drug currently available for the treatment. S. mansoni NTPDases (known as SmNTPDases, ATP diphosphohydrolases or ecto-apyrases) are potential drug targets for the discovery of new antischistosomal drugs. In this study, we screen NTPDases inhibitors from Centella erecta (Apiaceae) using an ultrafiltration combined UHPLC-QTOF-MS method and potato apyrase, identifying asiaticoside as one of the apyrase-binding compounds. After isolation of asiaticoside from C. erecta extract, we assessed its in vivo antischistosomal activities against Schistosoma mansoni worms and its in vitro enzymatic apyrase inhibition. Also, molecular docking analysis of asiaticoside against potato apyrase, S. mansoni NTPDases 1 and 2 were performed. Asiaticoside showed a significant in vitro apyrase inhibition and molecular docking studies corroborate with its possible actions in potato apyrase and S. mansoni NTPDases. In mice harboring a patent S. mansoni infection, a single oral dose of asiaticoside (400 mg/kg. p.o.) showed significantly in vivo antischistosomal efficacy, markedly decreasing the total worm load and egg burden, giving support for further exploration of apyrase inhibitors as antischistosomal agents.
- 17 May 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 1071
Open AccessIdentification of Asiaticoside from Centella erecta (Apiaceae) as Potential Apyrase Inhibitor by UF-UHPLC-MS and Its In Vivo Antischistosomal Activity
Schistosomiasis, caused by parasites of the genus Schistosoma, is a neglected disease with high global prevalence, affecting more than 240 million people in several countries. Praziquantel (PZQ) is the only drug currently available for the treatment. S. mansoni NTPDases (known as SmNTPDases, ATP diphosphohydrolases or ecto-apyrases) are potential drug targets for the discovery of new antischistosomal drugs. In this study, we screen NTPDases inhibitors from Centella erecta (Apiaceae) using an ultrafiltration combined UHPLC-QTOF-MS method and potato apyrase, identifying asiaticoside as one of the apyrase-binding compounds. After isolation of asiaticoside from C. erecta extract, we assessed its in vivo antischistosomal activities against Schistosoma mansoni worms and its in vitro enzymatic apyrase inhibition. Also, molecular docking analysis of asiaticoside against potato apyrase, S. mansoni NTPDases 1 and 2 were performed. Asiaticoside showed a significant in vitro apyrase inhibition and molecular docking studies corroborate with its possible actions in potato apyrase and S. mansoni NTPDases. In mice harboring a patent S. mansoni infection, a single oral dose of asiaticoside (400 mg/kg. p.o.) showed significantly in vivo antischistosomal efficacy, markedly decreasing the total worm load and egg burden, giving support for further exploration of apyrase inhibitors as antischistosomal agents.
- Open Access
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 58
Evaluation of copaiba oil as enhancer of ibuprofen skin permeation
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Pharmaceutical Sciences
- Vol. 58
Open AccessEvaluation of copaiba oil as enhancer of ibuprofen skin permeation
- Open Access
- 31 August 2021
- Published by Sociedade Unificada de Ensino Augusto Motta -UNISUAM in Revista Augustus
- Vol. 27 (54) , 96-108
POLÍTICA DE PROIBIÇÃO DA DIPIRONA
A dipirona é um dos analgésicos/antipiréticos mais utilizados no Brasil. Entretanto, devido às suspeitas de causar agranulocitose, esse medicamento foi retirado do mercado de mais de 30 países, incluindo: Estados Unidos, Japão, Austrália, e grande parte da União Europeia. Nosso objetivo foi questionar a proibição do medicamento. Dessa forma, foi realizada uma revisão comentada da literatura acerca das possíveis reações adversas e toxicidade associadas ao uso da dipirona bem como a polêmica questão relacionada à sua proibição. Apesar de a dipirona estar historicamente associada à ocorrência de agranulocitose, diversos estudos mostraram que quando comparada com outros analgésicos/antipiréticos disponíveis no mercado, esse fármaco apresenta melhor relação risco-benefício, além de possuir toxicidade em níveis aceitáveis. Em contrapartida, sua ampla disponibilidade, boa margem de segurança e baixo custo constituem-se importantes justificativas para seu uso e comercialização como medicamento isento de prescrição. Este ensaio discute ainda aspectos éticos, sociológicos e políticos que perpassam a proibição da dipirona.
- 31 August 2021
- Published by Sociedade Unificada de Ensino Augusto Motta -UNISUAM in Revista Augustus
- Vol. 27 (54) , 96-108
Open AccessPOLÍTICA DE PROIBIÇÃO DA DIPIRONA
A dipirona é um dos analgésicos/antipiréticos mais utilizados no Brasil. Entretanto, devido às suspeitas de causar agranulocitose, esse medicamento foi retirado do mercado de mais de 30 países, incluindo: Estados Unidos, Japão, Austrália, e grande parte da União Europeia. Nosso objetivo foi questionar a proibição do medicamento. Dessa forma, foi realizada uma revisão comentada da literatura acerca das possíveis reações adversas e toxicidade associadas ao uso da dipirona bem como a polêmica questão relacionada à sua proibição. Apesar de a dipirona estar historicamente associada à ocorrência de agranulocitose, diversos estudos mostraram que quando comparada com outros analgésicos/antipiréticos disponíveis no mercado, esse fármaco apresenta melhor relação risco-benefício, além de possuir toxicidade em níveis aceitáveis. Em contrapartida, sua ampla disponibilidade, boa margem de segurança e baixo custo constituem-se importantes justificativas para seu uso e comercialização como medicamento isento de prescrição. Este ensaio discute ainda aspectos éticos, sociológicos e políticos que perpassam a proibição da dipirona.
- Open Access
- 31 August 2021
- Published by Sociedade Unificada de Ensino Augusto Motta -UNISUAM in Revista Augustus
- Vol. 27 (54) , 96-108
POLÍTICA DE PROIBIÇÃO DA DIPIRONA
A dipirona é um dos analgésicos/antipiréticos mais utilizados no Brasil. Entretanto, devido às suspeitas de causar agranulocitose, esse medicamento foi retirado do mercado de mais de 30 países, incluindo: Estados Unidos, Japão, Austrália, e grande parte da União Europeia. Nosso objetivo foi questionar a proibição do medicamento. Dessa forma, foi realizada uma revisão comentada da literatura acerca das possíveis reações adversas e toxicidade associadas ao uso da dipirona bem como a polêmica questão relacionada à sua proibição. Apesar de a dipirona estar historicamente associada à ocorrência de agranulocitose, diversos estudos mostraram que quando comparada com outros analgésicos/antipiréticos disponíveis no mercado, esse fármaco apresenta melhor relação risco-benefício, além de possuir toxicidade em níveis aceitáveis. Em contrapartida, sua ampla disponibilidade, boa margem de segurança e baixo custo constituem-se importantes justificativas para seu uso e comercialização como medicamento isento de prescrição. Este ensaio discute ainda aspectos éticos, sociológicos e políticos que perpassam a proibição da dipirona.
- 31 August 2021
- Published by Sociedade Unificada de Ensino Augusto Motta -UNISUAM in Revista Augustus
- Vol. 27 (54) , 96-108
Open AccessPOLÍTICA DE PROIBIÇÃO DA DIPIRONA
A dipirona é um dos analgésicos/antipiréticos mais utilizados no Brasil. Entretanto, devido às suspeitas de causar agranulocitose, esse medicamento foi retirado do mercado de mais de 30 países, incluindo: Estados Unidos, Japão, Austrália, e grande parte da União Europeia. Nosso objetivo foi questionar a proibição do medicamento. Dessa forma, foi realizada uma revisão comentada da literatura acerca das possíveis reações adversas e toxicidade associadas ao uso da dipirona bem como a polêmica questão relacionada à sua proibição. Apesar de a dipirona estar historicamente associada à ocorrência de agranulocitose, diversos estudos mostraram que quando comparada com outros analgésicos/antipiréticos disponíveis no mercado, esse fármaco apresenta melhor relação risco-benefício, além de possuir toxicidade em níveis aceitáveis. Em contrapartida, sua ampla disponibilidade, boa margem de segurança e baixo custo constituem-se importantes justificativas para seu uso e comercialização como medicamento isento de prescrição. Este ensaio discute ainda aspectos éticos, sociológicos e políticos que perpassam a proibição da dipirona.
- 22 June 2021
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 60 (6) , 518-524
Simultaneous Monitoring of Azathioprine Metabolites in Erythrocytes of Crohn’s Disease Patients by HPLC-UV
The conversion of azathioprine (AZA) to active 6-thioguanine nucleotides (6-TGN) is essential for its clinical efficacy; however, another metabolite formed, 6-methylmercaptopurine (6-MMP), is related to hepatotoxicity. Blood samples were collected from 37 patients under AZA’s treatment, and a new HPLC-UV method was validated and applied for simultaneous quantification of 6-TGN and 6-MMP in erythrocytes of Crohn’s disease (CD) patients. The concentration of 6-TGN and 6-MMP found ranged from 4.5 to 2,456 ρmol/8 × 108 red blood cells (RBCs) for 6-TGN and from 170 to 53,951 ρmol/8 × 108 RBCs for 6-MMP. Reduced levels of 6-MMP in patients into combo therapy with AZA and allopurinol (2,031 ρmol/8 × 108 RBCs) have been observed when compared to patients undergoing monotherapy with AZA (9,098 ρmol/8 × 108 RBCs). Additionally, there was a negative correlation (r = −83.7%, P < 0.05) between lymphocyte count and 6-TGN levels. The method developed is reliable, accurate and reproducible and can be used as an important tool in the monitoring routine of patients with CD under AZA treatment, allowing the individualization of the dose, monitoring adherence to the treatment and the evaluation of the clinical outcome of these patients.
- 22 June 2021
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 60 (6) , 518-524
Simultaneous Monitoring of Azathioprine Metabolites in Erythrocytes of Crohn’s Disease Patients by HPLC-UV
The conversion of azathioprine (AZA) to active 6-thioguanine nucleotides (6-TGN) is essential for its clinical efficacy; however, another metabolite formed, 6-methylmercaptopurine (6-MMP), is related to hepatotoxicity. Blood samples were collected from 37 patients under AZA’s treatment, and a new HPLC-UV method was validated and applied for simultaneous quantification of 6-TGN and 6-MMP in erythrocytes of Crohn’s disease (CD) patients. The concentration of 6-TGN and 6-MMP found ranged from 4.5 to 2,456 ρmol/8 × 108 red blood cells (RBCs) for 6-TGN and from 170 to 53,951 ρmol/8 × 108 RBCs for 6-MMP. Reduced levels of 6-MMP in patients into combo therapy with AZA and allopurinol (2,031 ρmol/8 × 108 RBCs) have been observed when compared to patients undergoing monotherapy with AZA (9,098 ρmol/8 × 108 RBCs). Additionally, there was a negative correlation (r = −83.7%, P < 0.05) between lymphocyte count and 6-TGN levels. The method developed is reliable, accurate and reproducible and can be used as an important tool in the monitoring routine of patients with CD under AZA treatment, allowing the individualization of the dose, monitoring adherence to the treatment and the evaluation of the clinical outcome of these patients.
- 10 June 2020
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 16 (3) , 358-362
Improved Method for Obtaining of Arctigenin from Arctium Lappa L. and its Antiproliferative Effect on Human Hepatocarcinoma HepG2 Cells
Background: Arctigenin is a lignan found in Arctium lappa L. (Asteraceae) that displays anti-inflammatory activities. Previous studies showed that the crude extract of A. Lappa has antitumor activity in human liver carcinoma, lung and stomach cancer cells. The aim of this study was to obtain arctigenin from A. lappa L., as well as to evaluate its antiproliferative effects in cells of liver carcinoma (HepG2) and fibroblasts (NIH/3T3). Methods: Arctigenin was obtained from the hydrolysis of arctiin, which was isolated from the crude extract of A. lappa. The effects of arctigenin and arctiin on HepG2 cell viability and cell adhesion were analyzed by MTT method. Adhesion assay was also carried out to evaluate the antitumor activity. Results: Our results showed that the analytical process to obtain arctigenin was fast and easy. In vitro experiments showed that arctigenin (107-269 μM) decreased HepG2 cells viability and did not cause cytotoxicity on NIH/3T3 cells. Arctigenin (27-269 μM) demonstrated anti-adhesion in HepG2 cells in a concentration-dependent manner, when compared with control. Conclusion: These results suggest a promising pharmacological activity for arctigenin as an antiproliferative compound.
- 10 June 2020
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 16 (3) , 358-362
Improved Method for Obtaining of Arctigenin from Arctium Lappa L. and its Antiproliferative Effect on Human Hepatocarcinoma HepG2 Cells
Background: Arctigenin is a lignan found in Arctium lappa L. (Asteraceae) that displays anti-inflammatory activities. Previous studies showed that the crude extract of A. Lappa has antitumor activity in human liver carcinoma, lung and stomach cancer cells. The aim of this study was to obtain arctigenin from A. lappa L., as well as to evaluate its antiproliferative effects in cells of liver carcinoma (HepG2) and fibroblasts (NIH/3T3). Methods: Arctigenin was obtained from the hydrolysis of arctiin, which was isolated from the crude extract of A. lappa. The effects of arctigenin and arctiin on HepG2 cell viability and cell adhesion were analyzed by MTT method. Adhesion assay was also carried out to evaluate the antitumor activity. Results: Our results showed that the analytical process to obtain arctigenin was fast and easy. In vitro experiments showed that arctigenin (107-269 μM) decreased HepG2 cells viability and did not cause cytotoxicity on NIH/3T3 cells. Arctigenin (27-269 μM) demonstrated anti-adhesion in HepG2 cells in a concentration-dependent manner, when compared with control. Conclusion: These results suggest a promising pharmacological activity for arctigenin as an antiproliferative compound.
- 1 July 2018
- Published by Elsevier in Fitoterapia
- Vol. 128, 142-147
Pharmacokinetic profile and oral bioavailability of Kaurenoic acid from Copaifera spp. in rats
- 1 July 2018
- Published by Elsevier in Fitoterapia
- Vol. 128, 142-147
Pharmacokinetic profile and oral bioavailability of Kaurenoic acid from Copaifera spp. in rats